Galenfeha, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Marlowe Christopher Ryan, was filed 29 Mar 2018.
Galenfeha, Inc.: what insiders have been doing
Galenfeha, Inc. belongs to the Food & Agriculture sector. Filings by its managers are published through SEC (Form 4). The past year has been quiet: not a single insider filing for Galenfeha, Inc. The previous disclosure was published on 13 December 2021.
Since 2014, the database holds 15 purchases and 24 sales by insiders of the company.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2014FY ended December 2014 · cache
- 650,000 shares@ US$0.0914.0% of flowCommonSEC:0001062993-21-012794:1
- 2,045,100 shares@ US$0.09100.0% of flowCommonSEC:0001062993-21-012794:0
- 17,000 shares@ US$0.12100.0% of flowCommon StockSEC:0001062993-18-001405:0Canonical exit: 27 Jun 2018 (T+90)
- 45,000 shares@ US$0.0340.4% of flowCommon StockSEC:0001062993-18-000476:0Canonical exit: 7 May 2018 (T+90)
- 75,000 shares@ US$0.0410.8% of flowCommon StockSEC:0001062993-18-000410:0Canonical exit: 2 May 2018 (T+90)
- 580,000 shares@ US$0.0182.7% of flowCommon StockSEC:0001062993-18-000345:0Canonical exit: 26 Apr 2018 (T+90)
- 3,000,000 shares@ US$0.017.8% of flowPreferred Series BSEC:0001062993-18-000345:1
- 210,000 shares@ US$0.0352.0% of flowCommon StockSEC:0001062993-17-004505:0Canonical exit: 8 Jan 2018 (T+90)
- 170,000 shares@ US$0.3516.2% of flowCommon StockSEC:0001062993-17-004494:0Canonical exit: 8 Jan 2018 (T+90)
- 60,000 shares@ US$0.0360.6% of flowCommon StockSEC:0001062993-17-004097:0Canonical exit: 11 Dec 2017 (T+90)
- 45,000 shares@ US$0.040.5% of flowCommon StockSEC:0001062993-17-004006:0Canonical exit: 13 Nov 2017 (T+90)
- 50,000 shares@ US$0.0450.6% of flowCommon StockSEC:0001062993-17-003705:0Canonical exit: 9 Nov 2017 (T+90)
- 2,000,000 shares@ US$0.0316.5% of flowPreferred Series ASEC:0001062993-17-003565:0Canonical exit: 6 Nov 2017 (T+90)
- 35,000 shares@ US$0.060.6% of flowCommon StockSEC:0001062993-17-003565:1Canonical exit: 2 Nov 2017 (T+90)
- 1,800,000 shares@ US$0.028100.0% of flowCommonSEC:0001062993-16-011410:0
- 4,100,000 shares@ US$0.0012.4% of flowCommonSEC:0001062993-16-007097:0Canonical exit: 13 Apr 2016 (T+90)
- 2,500,000 shares@ US$0.10CommonSEC:0001062993-15-005575:0Canonical exit: 27 Dec 2015 (T+90)
- 1,254,150 shares@ US$0.128CommonSEC:0001062993-15-005109:0Canonical exit: 17 Dec 2015 (T+90)
- 1,600,000 shares@ US$0.169CommonSEC:0001062993-15-004992:0Canonical exit: 9 Dec 2015 (T+90)
- 15,426 shares@ US$0.383Common StockSEC:0001062993-14-005926:0
- 15,000 shares@ US$0.383Common StockSEC:0001062993-14-005926:1
- 5,000 shares@ US$0.379Common StockSEC:0001062993-14-005926:2
- 6,000 shares@ US$0.379Common StockSEC:0001062993-14-005858:0
- 5,250 shares@ US$0.379Common StockSEC:0001062993-14-005858:1
- 25,650 shares@ US$0.3835Common StockSEC:0001062993-14-005806:0
25 of 39 declarations
About Galenfeha, Inc.
Galenfeha, Inc. is a very small U.S. public company with a long and shifting corporate history, and it should be viewed as a speculative microcap rather than a mainstream NYSE/NASDAQ large-cap name. The company was incorporated in Nevada on March 14, 2013, and its executive offices are currently reported in Tallahassee, Florida, in the United States. For investors screening SEC Form 4 insider activity, the name is relevant primarily because of the insider/ownership dynamics typical of thinly traded issuers. ([otcmarkets.com](https://www.otcmarkets.com/file/company/financial-report/417103/content))
From an operating perspective, Galenfeha currently describes itself as being in the hemp cultivation and sales business, with a focus on developing hemp products infused with various items. Management also frames the company as a developer/acquirer of businesses that fit a “Developing, Scaling, and Financing” (DSF) model, suggesting a broader opportunistic capital-allocation approach rather than a single focused industrial franchise. In practical terms, that means investors should expect a story driven by corporate repositioning, small transactions, and financing needs more than by stable recurring revenues. ([otcmarkets.com](https://www.otcmarkets.com/file/company/financial-report/417103/content))
Read moreShow less
The company’s history helps explain this profile. Older SEC filings show that Galenfeha previously operated as an engineering, product development, and manufacturing company serving oil and natural gas production as well as stored-energy applications. Earlier public communications referenced LiFePO4 golf cart batteries, an intelligent chemical injection control system called iWaV, and distribution agreements in the oilfield equipment market. This indicates that the company has pivoted multiple times over the years, responding to changing market opportunities and capital availability. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1574676/000106299316008593/form10k.htm))
Geographically, the business remains U.S.-centric. Its reported headquarters/executive office base is in Florida, while its incorporation jurisdiction is Nevada. Historical SEC materials also show a prior executive address in Fort Worth, Texas, underscoring that the company’s footprint has been relatively flexible and asset-light. In 2022, Galenfeha disclosed that it had established a position in New Green Holdings, a hemp-related business, which aligns with the company’s recent repositioning toward the hemp theme. ([otcmarkets.com](https://www.otcmarkets.com/file/company/financial-report/417103/content))
In terms of recent developments, public disclosures remain sparse, which is common for microcaps, but the most recent OTC disclosure highlights going-concern pressure, negative working capital, and dependence on outside financing. That is an important analytical point for European investors: the equity story is highly sensitive to dilution risk, financing execution, and any insider-related filings such as Form 4 transactions. The company’s market position is therefore best characterized as niche, early-stage, and financially constrained, with upside tied to successful operational stabilization and credible capital formation. ([otcmarkets.com](https://www.otcmarkets.com/file/company/financial-report/417103/content))
